Category:
Other Excipients
CAS NO:
/
Standard:
In-house Standards,

indicated for the treatment of breast cancer, non-small cell lung cancer and chronic myeloid leukemia. "1, High efficacy, low toxicity and no cross resistance 2, Time to market: 2003 3, Sales in China reached 200 million US Dollars; 4, Technology transferred from ASTA Medica AG, Germany Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part."